Relevant Publications

Publication describing the preclinical efficacy of a novel, single-vial, bivalent vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections. In collaboration with University of Hawaiʻi at Mānoa (UHM), the manuscript entitled “Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection“, has been published in Vaccine. Read the publication.

An article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma (CTCL) published in Frontiers in Drug Discovery. The mini-review summarizes findings about the use, mechanism and effectiveness of HyBryte™ in the treatment of CTCL with a particular emphasis on the ability of HyBryte™ to address the unmet medical need in patients with early-stage disease. Read the publication.

The results of the successful Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) has been published in the Journal of the American Medical Association (JAMA) Dermatology. Read the publication.

In this interview, Dr. Christopher Schaber, President and Chief Executive Officer, discusses the Company’s pipeline with The Price of Business. To read or listen to the interview, click here.

CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARSCoV-2 Spike S1 Immunization

Read the Publication

In this article in Drug Target Review, Drs. Donini, Schaber, and Straube discuss innate immunity. To read the article, click here.

In this interview, Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses innate immunity and development of Innate Defense Regulator technology with Nature. To read the article, click here.

Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses the Company’s ricin toxin vaccine with ROI-NJ. To read the article please click here.

Read the publication (pdf)

In a recent article in BioWorld Today, the Soligenix ricin toxin vaccine program was reviewed, including comments from Dr. Oreola Donini, Chief Scientific Officer of Soligenix.

View the article here.

The publication of positive clinical results consistent with preclinical data

Read the publication (pdf)

Dr. Oreola Donini, Chief Scientific Officer of Soligenix, Inc. recently discussed the IDR technology and SGX942 with two publications.

Read the article in European Pharmaceutical Review

Read the article in Drug Target Review

The publication of data demonstrating the mechanism and broad-spectrum activity of dusquetide in preclinical bacterial infection models

Read the publication (pdf)

Dr. Christopher J. Schaber, President & CEO discusses ThermoVax™ technology and the vaccine market
Read the article

Dr. Oreola Donini, Chief Scientific Officer discusses SGX94
Read the publication (pdf)

Q&A with Dr. Christopher J. Schaber, President & CEO
Read the publication (pdf)

http://buywithoutprescriptiononlinerx.net/clomid.html

http://rxbuywithoutprescriptiononline.com/lasix.html

Drs. Schaber and Straube Discuss Treatment of Cutaneous T-Cell Lymphoma in Recent Publication
Read the publication (pdf)